Clinical Trials Logo

Systemic Lupus Erythematosus clinical trials

View clinical trials related to Systemic Lupus Erythematosus.

Filter by:

NCT ID: NCT02530944 Completed - Clinical trials for Systemic Lupus Erythematosus

Web-based Genetic Research on Lupus

Start date: May 2015
Phase: N/A
Study type: Observational

The goal of this new lupus research study is two-fold: first, to understand the genetic associations found between people's DNA and this disease, and second, to apply this understanding to drug development efforts with the investigator's partners at Pfizer.

NCT ID: NCT02525835 Withdrawn - Clinical trials for Systemic Lupus Erythematosus

Tissue Sodium in Autoimmune Disease

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

This pilot study will test the hypothesis that a low sodium diet will decrease sodium (23Na) magnetic resonance imaging-determined skin sodium concentrations in patients with systemic lupus erythematosus (SLE) and improve blood pressure and inflammation

NCT ID: NCT02524795 Completed - Clinical trials for Systemic Lupus Erythematosus

Omega 3 Fatty Acids and Systemic Lupus Erythematosus

OM3LES
Start date: March 2009
Phase: N/A
Study type: Interventional

Omega-3 fatty acids have been considered anti-inflammatory lipids based on data from epidemiological studies of Greenland Eskimos whose diet is rich in fish, sources of polyunsaturated fatty acids. Fatty acids from the omega-3 family [mainly the α-linolenic acid, eicosapentaenoic (EPA) and docosahexaenoic (DHA)], as well as those of the omega-6 family [represented mainly by linoleic acid and arachidonic acid (AA)] are essential for the synthesis of eicosanoids, prostaglandins, leukotrienes, thromboxanes and other oxidative factors, major mediators and regulators of inflammation. Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease characterized by the loss of balance of cellular immunoregulation and increased levels of circulating inflammatory mediators.Thus, omega-3 supplementation could represent additional therapy for individuals with SLE. The aim of this study was to investigate the effects of omega-3 fatty acids on circulating levels of inflammatory and biochemical markers in women with SLE.

NCT ID: NCT02514967 Terminated - Clinical trials for Systemic Lupus Erythematosus

CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Start date: June 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the clinical efficacy of blisibimod as measured by a composite responder index in subjects who, despite corticosteroid use, continue to have seropositive, clinically-active Systemic Lupus Erythematosus (SLE) as defined by SELENA-SLEDAI score ≥10, and positive for anti-double stranded DNA and low complement (C3 or C4).

NCT ID: NCT02477254 Completed - Clinical trials for Systemic Lupus Erythematosus

Long-term Immunogenicity of a HPV Vaccine in SLE

Start date: July 2015
Phase: N/A
Study type: Observational

To study the 5-year immunogenicity against a quadrivalent HPV vaccine in patients with SLE and healthy controls.

NCT ID: NCT02477150 Completed - Clinical trials for Systemic Lupus Erythematosus

Safety and Immunogenicity of a Zoster Vaccine in SLE

Start date: November 2015
Phase: Phase 4
Study type: Interventional

To study the safety and immunogenicity of a herpes zoster vaccine in patients with SLE.

NCT ID: NCT02472795 Completed - Clinical trials for Systemic Lupus Erythematosus

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

Start date: June 1, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

International trial to evaluate the biological activity and safety of cenerimod (ACT-334441) in systemic lupus erythematosus (SLE) patients.

NCT ID: NCT02465580 Recruiting - Clinical trials for Systemic Lupus Erythematosus

A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus

Start date: June 2015
Phase: Phase 2
Study type: Interventional

Dysfunction of regulatory T (Treg) cells has been detected in diverse autoimmune diseases, which can be promoted by interleukin-2 (IL-2). In a previous small sample trail performed by the investigator's group, the investigators found that the Low-dose IL-2 was effective and well tolerated in active SLE, and the effect was associated with selective modulation of CD4+ T cell subsets. This clinical study will confirm the efficacy and safety of low dose IL-2 treatment in SLE. The investigators perform a single-centre, double-blind pilot trial with hrIL-2 in SLE.The investigators evaluate the effectiveness and safeness of low-dose hrIL-2 for Systemic lupus erythematosus by randomized controlled study (hrIL-2 (N = 30) versus placebo group (N = 30)).

NCT ID: NCT02456168 Completed - Clinical trials for Systemic Lupus Erythematosus

Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus

Start date: January 21, 2014
Phase:
Study type: Observational

Cognitive impairment occurs in as many as 80% of lupus patients and affective disorders, depression and anxiety, are also common. Both of these problems contribute significantly to disease burden and disability. Associations between serum anti-NMDAR Aab and cognitive and behavioral changes in human SLE have remained controversial, however, elevated titers of these Aabs in cerebrospinal fluid (CSF) correlate with severe central nervous system manifestations, such as coma and psychosis. The aim is to study the progression of disease (cognitive and behavioral impairment) over a 2 year period in SLE subjects with neuropsychologic and behavioral testing and correlates of disease progression using resting FDG-PET and serum Anti-NMDAR Aab. The correlations between hippocampal hypermetabolism, Anti-NMDAR Aab and memory impairment observed in the cross-sectional studies will be validated by baseline measurements in the proposed studies.

NCT ID: NCT02453880 Completed - Depression Clinical Trials

Web-based CBT for Symptoms of Mild-to-Moderate Anxiety and Depression in Youth With Chronic Illness

Start date: January 2014
Phase: N/A
Study type: Interventional

Symptoms of anxiety and depression are common in adolescents and young adults with chronic illnesses and are associated with decreased adherence to medical regimens. However, many young patients go untreated for anxiety and depression. The purpose of this study is to evaluate an online cognitive behavioral therapy (CBT) program in young adults with chronic illness. Prior research has shown online CBT to be effective in multiple other populations, but to the investigators' knowledge, this is the first study to examine web-based CBT for young adults with chronic illnesses.